Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

628 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab in HER2-Positive Gastric Cancer.
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yañez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin S, Van Cutsem E, Tabernero J, Luo S, Mahave M, Tang Y, Lowery M, Monteiro MMF, Xu L, Shih CS, Sharan KP, Bhagia P, Rha SY. Janjigian YY, et al. Among authors: lonardi s. N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282917 Free PMC article. Clinical Trial. No abstract available.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Shitara K, et al. Among authors: lonardi s. Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19. Lancet Oncol. 2024. PMID: 38134948 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38579793
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Shitara K, et al. Among authors: lonardi s. N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. N Engl J Med. 2024. PMID: 39282934 No abstract available.
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.
Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Andre T, et al. Among authors: lonardi s. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141. N Engl J Med. 2024. PMID: 39602630 Clinical Trial.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Among authors: lonardi s. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, Pietrantonio F, Lonardi S, Gallois C, Taieb J. Ambrosini M, et al. Among authors: lonardi s. Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290. Epub 2024 Aug 22. Eur J Cancer. 2024. PMID: 39216175
Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcome.
Trahearn N, Sakr C, Banerjee A, Lee SH, Baker AM, Kocher HM, Angerilli V, Morano F, Bergamo F, Maddalena G, Intini R, Cremolini C, Caravagna G, Graham T, Pietrantonio F, Lonardi S, Fassan M, Sottoriva A. Trahearn N, et al. Among authors: lonardi s. J Pathol. 2025 Feb;265(2):198-210. doi: 10.1002/path.6378. J Pathol. 2025. PMID: 39788558
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy.
Vetere G, Germani MM, Antoniotti C, Salvatore L, Pietrantonio F, Lonardi S, Bensi M, Ghelardi F, Calegari MA, Intini R, Minelli A, Sullo FG, Boccaccio C, Taravella A, Puccini A, Lavacchi D, Noto L, Salati M, Scartozzi M, Cremolini C. Vetere G, et al. Among authors: lonardi s. Ther Adv Med Oncol. 2025 Jan 7;17:17588359241299975. doi: 10.1177/17588359241299975. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39776534 Free PMC article.
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors.
Taieb J, Ambrosini M, Alouani E, Lonardi S, Sinicrope FA, Decraecker M, Boileve A, Hafliger E, Mazard T, Pernot S, Parent P, Ros J, Overman MJ, Jayachandran P, Nasca V, Salvatore L, Guimbaud R, Cremolini C, Tougeron D, Pietrantonio F. Taieb J, et al. Among authors: lonardi s. J Immunother Cancer. 2025 Jan 4;13(1):e010424. doi: 10.1136/jitc-2024-010424. J Immunother Cancer. 2025. PMID: 39755579 Free article.
628 results